Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice:Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling by Arlt, Volker M. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.toxlet.2012.06.016
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Arlt, V. M., Poirier, M. C., Sykes, S. E., John, K., Moserova, M., Stiborova, M., ... Phillips, D. H. (2012). Exposure
to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null
(RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-
postlabelling. Toxicology Letters, 213(2), 160-166. 10.1016/j.toxlet.2012.06.016
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
                                                
 
Open Access document 
downloaded from King’s Research Portal 
https://kclpure.kcl.ac.uk/portal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The copyright in the published version resides with the publisher. 
 
When referring to this paper, please check the page numbers in the published version and cite these. 
General rights 
Copyright and moral rights for the publications made accessible in King’s Research Portal are 
retained by the authors and/or other copyright owners and it is a condition of accessing publications 
in King's Research Portal that users recognise and abide by the legal requirements associated with 
these rights.' 
• Users may download and print one copy of any publication from King’s Research Portal for 
the purpose of private study or research.  
• You may not further distribute the material or use it for any profit-making activity or 
commercial gain 
• You may freely distribute the URL identifying the publication in the King’s Research Portal 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
Citation to published version: 
Arlt, V. M., Poirier, M. C., Sykes, S. E., John, K., Moserova, M., Stiborova, 
M., Wolf, C. R., Henderson, C. J., & Phillips, D. H. (2012). Exposure to 
benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and 
P450 Reductase Conditional Null (RCN) mice: Detection of 
benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 
P-32-postlabelling. Toxicology Letters, 213(2), 160-166. 
 
The published version is available at: 
http://dx.doi.org/10.1016/j.toxlet.2012.06.016  
 
This version:  
https://kclpure.kcl.ac.uk/portal/en/publications/exposure-to-benzoapyrene-
of-hepatic-cytochrome-p450-reductase-null-hrn-and-p450-reductase-
conditional-null-rcn-mice-detection-of-benzoapyrene-dio-epoxidedna-
adducts-by-immunohistochemistry-and-32ppostlabelling%28876d7a44-
6598-4e3f-9288-c1ba7c01a69e%29.html  
 1
Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null 
(HRN) and P450 Reductase Conditional Null (RCN) mice: detection of 
benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 
32P-postlabelling 
 
Volker M. Arlta,*, Miriam C. Poirierb, Sarah E. Sykesb,c, Kaarthik Johnb, Michaela 
Moserovad, Marie Stiborovad, C. Roland Wolfe, Colin J. Hendersone and David H. 
Phillipsa 
 
aAnalytical and Environmental Sciences Division, MRC-HPA Centre for Environment and 
Health, King’s College London, London, United Kingdom. 
bCarcinogen-DNA Interactions Section, Laboratory of Cancer Biology and Genetics, 
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 
cSchool of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. 
dDepartment of Biochemistry, Faculty of Science, Charles University, Prague, Czech 
Republic. 
eDivision of Cancer Research, Medical Research Institute, Jacqui Wood Cancer Centre, 
University of Dundee, Dundee, United Kingdom. 
 
* Corresponding author. Tel: ++44 207 848 3781; Fax: ++44 207 848 4086. E-mail address: 
volker.arlt@kcl.ac.uk (V.M. Arlt) 
 
 
 
 
 
 
 
 
 2
Abstract  
Benzo[a]pyrene (BaP) is a widespread environmental carcinogen activated by cytochrome 
P450 (P450) enzymes. In Hepatic P450 Reductase Null (HRN) and Reductase Conditional 
Null (RCN) mice, P450 oxidoreductase (Por) is deleted specifically in hepatocytes, resulting 
in the loss of essentially all hepatic P450 function. Treatment of HRN mice with a single i.p. 
or oral dose of BaP (12.5 or 125 mg/kg body weight) resulted in higher DNA adduct levels in 
liver (up to 10-fold) than in wild-type (WT) mice, indicating that hepatic P450s appear to be 
more important for BaP detoxification in vivo. Similar results were obtained in RCN mice. 
We tested whether differences between hepatocytes and non-hepatocytes in P450 activity 
may underlie the increased liver BaP-DNA binding in HRN mice. Cellular localisation by 
immunohistochemistry of BaP-DNA adducts showed that HRN mice have ample capacity for 
formation of BaP-DNA adducts in liver, indicating that the metabolic process does not result 
in the generation of a reactive species different from that formed in WT mice. However, 
increased protein expression of cytochrome b5 in hepatic microsomes of HRN relative to WT 
mice suggests that cytochrome b5 may modulate the P450-mediated bioactivation of BaP in 
HRN mice, partially substituting the function of Por. 
 
Key words: Benzo[a]pyrene, Cytochrome P450, Cytochrome P450 oxidoreductase, DNA 
adducts, Immunohistochemistry, Polycyclic aromatic hydrocarbon 
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Abbreviations 
BaP, benzo[a]pyrene; BPDE, benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide; Cyt b5, 
cytochrome b5; CYP, cytochrome P450; HRN, Hepatic P450 Reductase Null; IHC, 
immunohistochemistry; mEH, microsomal epoxide hydrolase; PAH, polycyclic aromatic 
hydrocarbon; POR, cytochrome P450 oxidoreductase; RCN, P450 Reductase Conditional 
Null ; TLC, thin-layer chromatography;. 
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1. Introduction 
Environmental factors and individual genetic susceptibility play an important role in many 
human cancers (Wild, 2009). Polycyclic aromatic hydrocarbons (PAHs), of which 
benzo[a]pyrene (BaP) is the most commonly studied and measured, are formed by the 
incomplete combustion of organic matter (Baird et al., 2005). Human exposure to PAHs is 
unavoidable and environmental sources include tobacco smoking, ambient air pollution and 
diet (Phillips, 1999, 2002). Numerous epidemiological studies have implicated BaP and other 
PAHs are implicated as causative agents in human cancer, particularly lung and colon cancer 
(Gunter et al., 2007; IARC, 2010; Kucab et al., 2010). 
 
BaP requires metabolic activation prior to reaction with DNA, and DNA adduct formation is 
an essential step by which it and other carcinogenic PAHs exert their biological effects 
(Lemieux et al., 2011; Luch and Baird, 2005). The initial oxidation of BaP is catalysed by 
cytochrome P450 (P450)-dependent monooxygeneases, of which CYP1A1 and CYP1B1 are 
two of the most important enzymes in this process (Hamouchene et al., 2011). The resulting 
epoxide is then converted to a dihydrodiol by microsomal epoxide hydrolase (mEH), which 
leads, via further bioactivation by CYP1A1 or CYP1B1, to the formation of the ultimately 
reactive species, BaP-7,8-dihydrodiol-9,10-epoxide (BPDE). The expression of P450s, such 
as CYP1A1, is known to be up-regulated by the aryl hydrocarbon receptor (AHR) (Hockley 
et al., 2007). BaP can bind to and activate the AHR thereby enhancing its own metabolic 
activation. Ultimately, BPDE reacts with DNA, forming adducts preferentially at guanine 
residues; the most abundant DNA adduct is 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-
7,8,9,10-tetrahydro-BaP (dG-N2-BPDE) (Phillips, 2005). The level of BaP-DNA adducts in 
cells is most probably the result of a balance between their formation and their loss through 
DNA repair processes, cell turnover, and/or apoptosis. Collectively, BaP genotoxicity 
depends on various factors: (i) metabolism of BaP by phase I enzymes (activation) to reactive 
DNA-binding species; (ii) detoxification of reactive BaP metabolites by both phase I and 
phase II enzymes (conjugation); (iii) rate of repair of BaP-DNA adducts; and (iv) BaP-
induced expression of genes such as those encoding enzymes involved in 
activation/detoxification or in DNA damage response (Uno et al., 2004). 
  
In contrast to in vitro studies showing the role of Cyp1a1 in metabolic activation of BaP, 
several studies indicate that in vivo Cyp1a1 is more important in the detoxification than in the 
metabolic activation of BaP (Arlt et al., 2008; Uno et al., 2004; Uno et al., 2001). It has been 
 5
found that Cyp1a1(-/-) mice administered repeated oral doses of BaP (125 mg/kg body 
weight [bw]/day) die within approximately 28 days due to immunosuppression, whereas 
wild-type (WT) mice thus treated remain healthy for at least 1 year on this regimen (Uno et 
al., 2004). Using the Hepatic P450 Reductase Null (HRN) mouse model we also showed that 
hepatic P450 enzymes appear to be more important for detoxification of BaP in vivo (Arlt et 
al., 2008). In HRN mice P450 oxidoreductase (Por), the electron donor to P450s, is deleted 
specifically in hepatocytes, resulting in the loss of essentially all hepatic P450 function 
(Henderson et al., 2003); we found that the levels of dG-N2-BPDE in livers of these mice 
treated intraperitoneally with BaP were higher than in WT mice (Arlt et al., 2008). 
 
The metabolic process (i.e. the specific enzyme(s) involved) by which DNA-binding species 
are generated in liver from BaP in HRN mice is not known, but it is clear that the process 
does not result in the generation of a different reactive species from that which is formed in 
WT mice. One hypothesis is that cell-specific differences in the activity of Cyp enzymes 
responsible for the metabolic activation of BaP in the liver (e.g. hepatocytes versus non-
hepatocytes) may underlie the increased DNA binding by BaP in the livers of HRN mice. 
However, using our previous analysis of DNA adduct formation, 32P-postlabelling or mass 
spectrometry, it is difficult to answer this question because DNA is extracted from whole 
tissue. Thus, in the present study we have used immunohistochemistry (IHC) staining with 
anti-BPDE-DNA antiserum (John et al., 2009; Pratt et al., 2011; Pratt et al., 2007; van Gijssel 
et al., 2002) to explore the localisation of BaP-derived DNA adducts within the liver of HRN 
mice. In addition, we have studied BaP-DNA adduct formation by 32P-postlabelling in a 
second mouse model, the P450 Reductase Conditional Null (RCN) mouse (Finn et al., 2007), 
to confirm results previously obtained in the HRN mouse model. 
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2. Materials and methods 
2.1. Chemicals 
BaP (>96%) was purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were 
of analytical purity or better.  
 
2.2. Animal treatment 
All animal experiments were carried out under license in accordance with the law, and with 
local ethical approval.  
 
HRN (Porlox/lox/CreALB) mice on a C57BL/6 background used in this study were derived as 
described previously (Henderson et al., 2003). Mice homozygous for loxP sites at the Por 
locus (Porlox/lox) were used as wild-type (WT). BaP was dissolved in corn oil at a 
concentration of 1.25 or 12.5 mg/mL. Groups of female HRN and WT mice (3 months old, 
25-30 g) were treated i.p. or orally with 12.5 or 125 mg/kg bw BaP (n=3) for 1 day. Control 
mice (n=3) received corn oil only. Animals were killed 24 hours after the single dose. Several 
organs (liver, lung, forestomach, glandular stomach, kidney, spleen and colon) were 
removed, snap frozen and stored at −80ºC until analysis. For IHC organ sections of the liver 
were fixed in PBS containing 4% paraformaldehyde, and subsequently subjected to paraffin 
embedding and sectioning.  
 
RCN (Porlox/lox/CreCYP1A1) mice (Finn et al., 2007) on a C57BL/6 background were bred in-
house at the Medical Research Institute (Dundee, UK). In brief, Por floxed mice (Porlox/lox) 
(Henderson et al., 2003) were crossed with a transgenic line expressing Cre recombinase 
under the control of the rat CYP1A1 promoter (Ireland et al., 2004) to generate the mouse 
line (Porlox/lox/CreCYP1A1). Pretreatment of RCN mice with 3-methylcholanthrene (3-MC; 40 
mg/kg bw i.p. in corn oil) 2 weeks before BaP treatment resulted in hepatic POR loss (Arlt et 
al., 2011). BaP was dissolved in corn oil at a concentration of 12.5 mg/mL. Groups of female 
RCN mice (3 months old, 25-30 g) were treated i.p. with 125 mg/kg bw (n=3) of BaP for 1 
day. Control mice (n=3) received corn oil only. Animals were sacrificed 24 hours after the 
single dose. Organs for 32P-postlabelling were collected as described above. 
 
2.3. BaP-DNA adduct detection by 32P-postlabelling analysis 
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Genomic DNA from whole tissue was isolated by a standard phenol-chloroform extraction 
method and DNA adducts were measured for each DNA sample using the nuclease P1 
enrichment version of the 32P-postlabelling method as described previously (Arlt et al., 2008; 
Phillips and Arlt, 2007).  
 
2.4. BaP-DNA adduct detection by immunohistochemistry 
Rabbit polyclonal antibodies, elicited against BPDE-modified DNA (rabbit#30 bleed 
6/30/78) (Poirier et al., 1980; Pratt et al., 2011; Weston et al., 1989), were employed for 
detection of dG-N2-BPDE. For IHC, the BPDE-DNA antiserum was pre-absorbed with calf-
thymus DNA to reduce non-specific background staining. In addition, some of the specific 
BPDE-DNA antiserum was absorbed with the immunogen BPDE-modified DNA (1.3% 
modified, 13.9 nmol dG-N2-BPDE adducts) so as to eliminate the specific BPDE-DNA 
immunoglobulins. This was used as a control for unknown samples. 
 
Three serial 5 µm sections (a, b, c) of paraffin-embedded liver tissue were mounted on 
positively charged glass slides, which were incubated at 60°C for 1 hr, deparaffinized by a 
series of xylene/ethanol washes, and subjected to antigen retrieval by microwaving in the 
presence of Antigen Retrieval Citra solution (Biogenex, San Ramon, CA). Subsequently, 
slide “a” was stained with specific BPDE-DNA antiserum, absorbed only with calf thymus 
DNA; slide “b” was stained with haematoxylin, for visualization of the nuclei; and, slide “c” 
was stained with BPDE-DNA antiserum absorbed with immunogen BPDE-DNA and 
unmodified DNA. Rabbit antisera were diluted 1:20,000 in antibody diluent (Ventana 
Medical Systems Inc., Tucson, AZ) before use. 
 
Slides were stained using the Nexes IHC (Ventana Medical Systems Inc.) automated slide 
staining system as previously described (van Gijssel et al., 2004). The antiserum incubation 
was for 20 min (for slides “a” and “c”) with no counterstaining. Slide “b” was incubated with 
normal rabbit serum and counterstained with modified haematoxylin-OS, a modified form of 
Mayer’s haematoxylin (Vector Labs, Burlingame, CA, USA) for 1 minute. Stained slides 
were subsequently rinsed for 1 min in water containing Dawn dishwashing liquid soap 
(Proctor and Gamble, Cincinnati, OH), and rinsed 3-4 times in deionized water to remove the 
soap. The stained slides were subsequently air dried, and mounted with cover slips using 
Permount mounting media (Fisher Scientific) and subsequently scanned at 20× resolution 
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using the ScanScope AT digital scanner (Aperio, Vista, CA, USA). The ‘digital’ scans of the 
slides were subsequently maintained on the ‘Spectrum’ database (Aperio) and visualized 
using ImageScope software (Aperio) .  
 
2.5. Expression of xenobiotic-metabolising enzymes by Western blotting 
HRN and WT mice were treated i.p. daily for 5 days with 125 mg/kg bw BaP (n=3) as 
described previously (Arlt et al., 2008). Control mice (n=3) received corn oil only. Hepatic 
microsomes from HRN and WT mice were isolated as reported. Pooled microsomal fractions 
were used for further analysis. Western blot analysis of cytochrome b5 (Cyt b5) and 
microsomal epoxide hydrolase (mEH) 
was performed using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE); 75 µg microsomal protein was subjected to 15% SDS-PAGE. After migration, 
proteins were transferred onto polyvinylidene difluoride (PVDF) membranes. Cytochrome b5 
protein was probed with rabbit polyclonal anti-cytochrome b5 antibody (1:750; ab69801; 
Abcam, MA, USA) and mEH with rabbit polyclonal anti-EH antibody (1:1000; ab76226; 
Abcam) overnight at 4°C. Glyceraldehyde phosphate dehydrogenase (GAPDH; 1:750; 
Millipore, MA, USA) was used as loading control. The antigen-antibody complex was 
visualised with an alkaline phosphatise-conjugated goat anti-rabbit IgG antibody and 5-
bromo-4-chloro-3-indolylphosphate/nitrobluetetrazolium as chromogenic substrate (Kotrbova 
et al., 2011; Stiborova et al., 2002). 
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3. Results  
3.1. DNA adduct formation in mice 
The DNA adduct pattern in organs (liver, lung, forestomach, glandular stomach, kidney, 
spleen and colon) of HRN and WT mice treated i.p. or orally with a single dose of BaP (12.5 
or 125 mg/kg bw) consisted of a single spot analysed by TLC-32P-postlabelling, previously 
identified as dG-N2-BPDE (Arlt et al., 2008). No DNA adducts were detected in control 
animals (data not shown). DNA adduct formation was dose-dependent both after i.p. and oral 
treatment (Figure 1). After i.p. administration the results at the higher dose were in 
concordance with our previous study (Arlt et al., 2008) showing a ~10-fold higher DNA 
binding by BaP in the livers and elevated levels in several extra-hepatic tissues of HRN mice 
(i.e. lung, glandular stomach, spleen and colon) compared with WT mice (Figure 1A). At the 
lower dose BaP-DNA adduct levels were substantially lower in all tissues, but as with the 
higher dose they were higher (~8-fold) in the livers of HRN mice than in WT mice (Figure 
1C). However, differences between HRN and WT mice in DNA adduct formation were not 
observed in extra-hepatic tissues with the lower dose of BaP. After oral administration of 
12.5 or 125 mg/kg bw BaP, DNA adduct formation by BaP was overall lower compared to 
i.p. administration (compare Figure 1B and 1D). Again, DNA binding by BaP in the livers of 
HRN mice was higher relative to WT mice, but this effect was less pronounced (only ~2-
fold)  than after i.p. administration. Overall, no difference in DNA binding by BaP was 
observed in extra-hepatic tissues, independent of the dose, except for the colon in the higher 
dose group which showed 3-fold elevated DNA adducts in HRN mice relative to WT mice 
(Figure 1B). 
 
After treatment of RCN mice with a single i.p. dose of 125 mg/kg body weight BaP, the DNA 
adduct pattern on TLC again consisted of a single spot (i.e. dG-N2-BPDE) with all organs 
from BaP-treated animals (Figure 2, insert), whereas no DNA adducts were detected in 
control animals (data not shown). Quantitative analysis revealed that BaP-induced DNA 
adduct levels were significantly higher (~6-fold) in livers of RCN mice that lack hepatic Por 
activity compared to RCN mice with active Por; elevated adduct levels (~2-fold) were also 
found in all extra-hepatic tissues (Figure 2). Interestingly, elevated levels of DNA adducts 
were found in kidney of RCN mice that lack hepatic Por activity, however, no difference in 
DNA adduct levels in the kidney were observed in the HRN model (compare Figure 1).  
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IHC has the capacity to show localisation of adducts, and to show magnitude of adduct 
formation by differences in colour intensity. Figure 3 shows liver sections from BaP-treated 
(at 125 mg/kg body weight, i.p.) WT (Figure 3A) and HRN (Figure 3D) mice incubated with 
the specific anti-BPDE-DNA antiserum, and showing nuclear pink colour intensity indicating 
BaP-derived DNA adducts. In Figure 3B and 3E, adjacent sections from WT and HRN mouse 
livers, respectively, were stained with the immunogen (BPDE-DNA)-absorbed anti-BPDE-
DNA antiserum, and the pink nuclear staining disappeared, indicating that the specific 
staining was due to BaP-derived DNA adducts. Further evidence that the nuclear staining 
observed in Figures 3A and 3D is specific is shown in Figure 3C and 3F, where unexposed 
WT and HRN mice, respectively, showed no evidence of BaP-derived DNA adducts. 
Therefore the staining shown in Figure 3A and 3D shows nuclear localisation of BaP-derived 
DNA adducts; the fact that the adducts were nuclear was confirmed by blue staining of the 
nuclei with haematoxylin (Data not shown). The adduct signal in the HRN (Figure 3D) mice 
was much stronger compared to the WT (Figure 3A) mice but experimental conditions did 
not allow any further semi-quantitation; the effect was so striking that the difference were 
strongly evident without talking any additional steps. These observations correspond well 
with the DNA adduct data obtained by 32P-postlabelling. While Figure 3 shows a 
representative mouse from each group, all 3 mice from each group showed similar patterns of 
staining (data not shown). As there were relatively few non-hepatocytes, we were not able to 
distinguish a difference in nuclear BaP-derived DNA adduct staining between hepatocytes 
and non-hepatocytes in livers from either WT or HRN mice.  
 
3.2. The effect of BaP on expression of hepatic biotransforming enzymes 
Using Western blot analysis we previously examined the protein expression levels of the 
BaP-activating enzymes Cyp1a1 and prostaglandin H synthase (Ptgs) as well as Por in 
hepatic microsomes isolated from HRN and WT mice treated with 125 mg/kg bw BaP for 5 
days (Arlt et al., 2008). To investigate further the role of BaP-metabolising enzymes we 
determined the expression of mEH and a component of a Cyp-monooxygenase system, 
cytochrome b5 (Cyt b5) (Yamazaki et al., 2002), in the same samples (Figure 4). The levels of 
mEH were ~2.4-fold higher in hepatic microsomes isolated from HRN relative to WT mice; 
expression of mEH was induced (~1.3-fold in HRN mice) by BaP treatment. Levels of 
cytochrome b5 were higher (~1.4 fold) in hepatic microsomes from HRN mice relative to WT 
mice. In addition, treatment with BaP increased the expression by ~1.6-fold in both HRN and 
WT mice.  
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4. Discussion 
We have previously used the HRN model to investigate hepatic versus extra-hepatic P450-
mediated carcinogen metabolism (Arlt et al., 2006; Arlt et al., 2005; Arlt et al., 2008; Levova 
et al., 2011; Stiborova et al., 2008). We found that hepatic P450s seem to be more important 
for detoxification of BaP in vivo despite being important for its bioactivation in vitro (Arlt et 
al., 2008). Compared to WT mice, BaP-DNA adduct levels were up to 13-fold higher in liver, 
and elevated in several extra-hepatic tissues, of HRN mice relative to WT mice, after a single 
i.p. dose of 125 mg/kg bw BaP.  
 
In HRN mice, the deletion of the Por gene occurs neonatally and although HRN mice 
develop normally, they exhibit a number of phenotypic changes associated with the loss of 
P450 function, including hepatic lipid accumulation, reduced bile acid production, increased 
constitutive P450 expression, and decreased plasma cholesterol and triglyceride levels 
(Henderson et al., 2003), which may have an impact on the pharmacokinetics/metabolism of 
xenobiotics studied. In RCN mice, hepatic Por can be deleted conditionally using a rat 
CYP1A1 promoter to drive Cre recombinase expression (Finn et al., 2007). Thus the use of 
this promoter provides a tightly regulated method for controlling expression of the transgene 
in vivo shortly before the animal experiment by the administration of an inducer (i.e. 3-MC) 
that acts through the aryl hydrocarbon receptor. In addition, RCN mice can be used as their 
own control. As shown previously, administration of 40 mg/kg bw (i.p.) 3-MC led to a 
complete and specific deletion of the hepatic Por gene within 14 days; no expression of Por 
was observed by Western blotting in hepatic microsomes isolated from RCN mice pretreated 
with 3-MC (Arlt et al., 2011). Further, it is noteworthy that 14 days after a single i.p. dose of 
40 mg/kg bw 3-MC, there is no hepatic Cyp1a protein evident (Finn et al., 2007), although 
some other hepatic Cyps are induced, consistent with the elevated hepatic P450 expression 
seen in the HRN model and driven by lipid accumulation (Finn et al., 2009). Collectively our 
results indicate that the previously observed phenomenon, whereby hepatic P450 enzymes 
appear to more important for BaP detoxification in vivo, is also seen at considerably lower 
BaP doses in the HRN model. Further, results obtained in the RCN model fully confirm the 
data obtained in the HRN mouse model.  
 
In general, i.p. administration results in the uptake of BaP by mesenteric veins and lymphatic 
system that go directly to the liver, bypassing the gastrointestinal tract. It has been pointed 
out that important pharmacokinetic differences depend on the route of administration (Uno et 
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al., 2004). After oral administration, BaP uptake should be via the gastrointestinal tract and 
hence to the liver. Indeed, DNA adduct formation after oral administration of BaP was 
overall lower compared with i.p. administration. Again, DNA binding by BaP in the livers of 
HRN mice was higher than in WT mice, but this effect was less pronounced than after i.p. 
administration, indicating that after oral administration the first-pass metabolism of BaP 
occurs in the gastrointestinal tract.  
 
The metabolic process (i.e. the specific enzyme(s) involved) by which DNA-binding species 
are generated by BaP in the liver of HRN mice (or RCN mice lacking hepatic POR) in the 
present study is not known, but it is clear that the process did not result in the generation of a 
reactive species different from that formed in WT mice. One hypothesis was that cell-specific 
differences in the activity of P450 enzymes responsible for the metabolic activation of BaP 
may underlie the increased DNA binding by BaP in the livers of HRN mice. We used IHC to 
investigate the localisation of BaP-derived DNA adducts within the liver (i.e. hepatocytes 
versus non-hepatocytes). This may be of importance as in the HRN mouse model hepatic Por 
is only deleted in hepatocytes which account for the majority of cells in the liver. However, it 
is clear from the 32P-postlabelling analysis, and confirmed by IHC, that HRN mice have 
ample capacity for formation of BaP-derived DNA adducts in their liver.  
 
Since hepatic P450 enzyme activity had been essentially obliterated by the conditional 
deletion of Por in hepatocytes, the level of BaP activation to DNA adducts in hepatocytes in 
HRN mice is difficult to rationalize. Our studies and those of others (Kondraganti et al., 
2003; Sagredo et al., 2009) may suggest that metabolic activation of BaP in vivo is mediated 
by P450-independent and/or Ahr-independent pathways, but our own studies have shown that 
the end result, i.e. the nature of the DNA adduct (i.e. dG-N2-BPDE) formed, is the same. BaP 
is a good substrate not only for CYP1A1 but also for prostaglandin H synthase (PTGS). 
However, we previously found no protein expression of Ptgs1 or Ptgs2 in hepatic microsomes 
of HRN and WT mice (Arlt et al., 2008). Microsomal epoxide hydrolase (mEH) is important 
for the hydrolysis of the BaP-7,8-epoxide formed during P450-mediated oxidation generating 
BaP-7,8-dihydrodiol which subsequently leads to the formation of BPDE, the ultimate 
reactive metabolite binding covalently to DNA. The levels of mEH were ~2.4-fold higher in 
hepatic microsomes isolated from HRN relative to WT mice (Figure 4); expression of mEH 
was induced (~1.3-fold in HRN mice) by BaP treatment. These findings indicate that the 
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different expression of mEH in HRN and WT mice might be one reason contributing to the 
increased DNA adduct formation by BaP in HRN mice.   
 
For many years microsomal cytochrome b5 (Cyt b5) has been proposed to modulate the 
activity of P450 enzymes (Schenkman and Jansson, 2003). The modulation of P450 activity 
by cytochrome b5 is reported to be both substrate- and P450-specific, with evidence of both 
stimulation and inhibition of substrate metabolism (Yamazaki et al., 2002). Two mechanisms 
of cytochrome b5-mediated modulation of P450 catalysis have been suggested: it can affect 
the P450 catalytic activities by donating the second electron to P450 in a P450 catalytic cycle 
and/or act as an allosteric modifier of the oxygenase. We previously found that hepatic Cyp1a 
protein induction was higher in HRN mice compared to WT mice, while, EROD activity, a 
measure for Cyp1a-mediated enzyme activity, was ~3.4-fold lower in microsomes isolated 
from livers of BaP-treated HRN mice relative to BaP-treated WT mice (Arlt et al., 2008). In 
the present study we found that the protein levels of cytochrome b5 were higher (~1.4 fold) in 
hepatic microsomes from HRN mice relative to WT mice (Figure 4). In addition, treatment 
with BaP increased the expression by ~1.6-fold in both HRN and WT mice. Thus, in HRN 
mice cytochrome b5 may not only modulate the P450-mediated (i.e. Cyp1a1) bioactivation of 
BaP in vivo, basically partially substituting Por in its function, but it may also stimulate P450-
mediated metabolic activation of BaP because of its increased expression induced by BaP. 
This hypothesis is in concordance with recent findings that cytochrome b5 causes a shift in 
the oxidation by CYP1A1 and CYP1A2 of the anticancer drug ellipticine from detoxification 
to activation, leading to increased DNA adduct formation by ellipticine in vitro (Kotrbova et 
al., 2011). Therefore, it would be interesting to examine the potential role of cytochrome b5 in 
the metabolic activation of BaP in vivo. Recently, a mouse model has been developed in 
which cytochrome b5 has been deleted in all tissues [cytochrome b5 complete null (BCN)] 
(McLaughlin et al., 2010), allowing investigation of the general function of cytochrome b5  in 
BaP metabolism in vivo. To dissect the role of hepatic cytochrome b5 versus hepatic Por in 
Cyp-mediated BaP bioactivation a liver-specific cytochrome b5 conditional knockout mouse 
(Cytb5lox/lox/CreALB; HBN mouse) has been generated (Finn et al., 2008) with or without the 
expression of hepatic Por (Henderson and Wolf, unpublished data). In the future we will test 
BaP in these mouse models, which potentially provide improved models to investigate the 
balance between P450-mediated activation and detoxification of BaP in vivo. 
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Legends to Figures 
 
Figure 1: 
Quantitative TLC 32P-postlabelling analysis of dG-N2-BPDE adducts in organs of HRN and 
WT mice treated i.p (A and C) or orally (B and D) with 12.5 (C and D) or 125 mg/kg bw BaP 
(A and B) for 24 hours. F=fold increase in DNA binding in HRN mice compared to WT 
mice. Values are given as means ± SD (n=3); each DNA sample was determined by two 
postlabelled analyses. Comparison was performed by t-test analysis: * P<0.01 different from 
WT. RAL, relative adduct labelling. 
 
Figure 2: 
Quantitative TLC 32P-postlabelling analysis of dG-N2-BPDE adducts in organs of RCN mice 
treated i.p with 125 mg/kg bw BaP for 24 hours without and with 3-MC pretreatment (single 
dose of 40 mg/kb bw 3-MC 14 days before BaP treatment. F=fold increase in DNA binding 
in RCN mice treated with BaP compared with RCN mice treated with BaP and inducer (i.e. 
3-MC). Values are given as means ± SD (n=3); each DNA sample was determined by two 
postlabelled analyses. Comparison was performed by t-test analysis: * P<0.01 different from 
RCN mice treated with BaP but without inducer. RAL, relative adduct labelling. Inset: 
Typical autoradiographic profile of BaP-derived DNA adducts obtained by 32P-postlabelling; 
solvent conditions for the resolution of 32P-labelled adducts on polyethyleneimine-cellulose 
thin-layer chromatography were: D1, 1.0 M sodium phosphate, pH 6; D3, 4.0 M lithium 
formate, 7.0 M urea, pH 3.5; D4, 0.8 M LiCl, 0.5 M Tris, 8.5 M urea, pH 8. The arrow 
indicates the position of the 5’-32P-labelled biphosphate dG-N2-BPDE adduct. ##, not 
determined (DNA sample lost).  
 
Figure 3: 
Immunostaining (× 20) for BPDE-DNA adducts in hepatic tissue sections of HRN and WT 
mice treated i.p. with 125 mg/kg bw BaP for 24 hours. Staining of BaP-treated mice (A and 
D) with specific BPDE-DNA antiserum; the arrows indicate stained nuclei detecting dG-N2-
BPDE adducts. Staining of BaP-treated mice (B and E) with BPDE-DNA-absorbed BPDE-
DNA antiserum (background). No staining was observed in control (untreated) animals (C 
and F). 
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Figure 4: 
Expression of mEH and cytochrome b5 (Cyt b5) in livers of HRN and WT mice, control 
(untreated) mice or mice treated i.p. daily with 125 mg/kg bw BaP for 5 days. Pooled hepatic 
microsomal samples were used for analyses as described in Material and Methods. Values are 
given as means ± SD of 3 determinations.   
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